What question did this study set out to answer?

To evaluate the effectiveness of CDK4/6 inhibitors in improving overall survival in metastatic breast cancer using target trial emulation.

March 10, 2026Breast Cancer Research and Treatment0 citationsOpen Access

Comparative effectiveness of CDK4/6 inhibitors in metastatic breast cancer: using the target trial emulation framework to investigate overall survival in routine care

ABA Brufsky RFRichard S. Finn OMOtto Metzger

Key Points

To evaluate the effectiveness of CDK4/6 inhibitors in improving overall survival in metastatic breast cancer using target trial emulation.
Utilized target trial emulation framework
Compared overall survival with palbociclib/ribociclib/abemaciclib plus AI
Leveraged real-world data for analysis
Overall survival was similar for all CDK4/6 inhibitors combined with AI
Findings highlight the potential for optimizing clinical strategies
Can inform clinical decision-making regarding breast cancer treatments

Abstract

Using target trial emulation, real-world OS is similar with palbociclib/ribociclib/abemaciclib plus AI. These findings may contribute to the development of combination strategies to improve clinical outcomes and to guide clinical decision-making.

AI से पूछें

Bookmark

View Full Paper